Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Core One Labs Inc C.COOL

Alternate Symbol(s):  CLABF

Healthcare Cannabis Psychedelics
Core One Labs Inc. is a Canada-based life sciences biotechnology research and development company. The Company is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of delivery systems technology. Its subsidiary, Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its subsidiary Akome Biotech Ltd., and three provisional patents under its other subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods. It also holds an interest in four medical clinics, which maintain a combined database of more than 275,000 patients.


CSE:COOL - Post by User

Core One Labs Inc
Bullboard Posts
User Avatar Image
(29)
•••
Comment by bullman246on Sep 22, 2018 11:32am
53 Views
Post# 28670280

RE:What is with this banking thing?

RE:What is with this banking thing?I thought so too. However, as soon as you think LDS has no more obstacles to overcome, SURPRISE! Another obstacle appears totally by surprise.

If this banking issue is no big deal, then why did Phil seemed concerned, and tell me the other day, that LDS is now going through CSPA rather than LDS for future news releases, and is very careful about releasing any financial information, due to tightening banking regs regarding Canadian cannabis companies operatring in the US.

So, here we are invested in a  company that is afraid to post new and release financial information to shareholders. Who ever heard of such a thing?

Just never ending risk after risk with this lousy stock. How is it that other cannabis companies are doing well, the cannabis sector is again booming, and many are expanding to additional states. 

I curse the day, I ever got involved with this stock, and the CannaStrips that never seem to ship or sell.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities